About Skyhawk Therapeutics

We are pioneering a new class of RNA-targeted small molecule therapies to address the world's most intractable diseases.

Our Mission

RNA mis-expression is a root cause of many of the world's most devastating diseases — including Huntington's disease, ALS, cancer, and fibrotic conditions. Yet the vast majority of disease-relevant proteins remain undruggable by conventional approaches. Skyhawk is changing that. We discover and develop small molecules that precisely modify RNA expression, unlocking a new universe of therapeutic targets and offering hope to patients who have no other options.

Who We Are

Leadership Team

Clint Musil

Chief Executive Officer

Mr. Musil brings decades of experience in the biopharmaceutical industry, with significant expertise in strategic planning, financial management, and business development. He previously served as Skyhawk's CFO from December 2021 through February 2024, and prior to that completed multiple IPOs and held executive roles at ARMO Biosciences, which was acquired by Eli Lilly for $1.6 billion. M.B.A. from Harvard Business School; B.S. in Molecular and Cellular Biology from University of Arizona.

Bill Haney

Co-founder and Executive Chairman

Mr. Haney co-founded Skyhawk Therapeutics after decades of entrepreneurial experience and founding more than a dozen technology companies. He also serves as CEO and Chairman of the Board at Dragonfly Therapeutics, and is a founding member of the EPA's National Environmental Advisory Board and President's Circle for National Academy of Sciences. Kennedy School Fellow (1997–2001); A.B. from Harvard College.

Chris LeMasters

Chief Operating Officer

Mr. LeMasters serves as Chief Operating Officer, overseeing Skyhawk's operational functions across research, development, and business operations. He joined Skyhawk as part of the June 2024 leadership expansion.

Rasmus Holm-Jorgensen, PhD, DVM

Chief Strategy Officer

Dr. Holm-Jorgensen has more than 25 years of experience in strategy, finance, portfolio management, and business development. Previously CFO at Acrivon Therapeutics and a founding team member of Kiniksa Pharmaceuticals. Also led a global commercial turnaround at GN Group and held senior roles at Novo Nordisk across Denmark, the U.S., Brazil, and Mexico. M.S. in Economics, University of Copenhagen; executive training at INSEAD, Stanford, and Harvard Business School.

Dr. Elliot Ehrich, MD

Chief Medical Officer

Dr. Ehrich was most recently Venture Partner at 5AM Ventures and CMO at Expansion Therapeutics. Prior to that, he spent 17 years at Alkermes as Executive Vice President of R&D and CMO, leading development and FDA registration of multiple new medicines. BA in biochemistry from Princeton; MD from Columbia University; internal medicine residency and immunology fellowship at Stanford.

Dr. Joseph Duffy, PhD

Senior Vice President of Chemistry

Dr. Duffy was most recently Executive Director of Discovery Chemistry at Merck Research Laboratories, where he spent 24 years overseeing preclinical drug discovery teams across all phases from lead identification through clinical candidate development. B.Sc. in Chemistry from Kent State University; Ph.D. from Harvard University.

Scientific Advisory Board

Dr. Tyler Jacks

Founding SAB Chairman; Professor of Biology, MIT

Founder of the David H. Koch Institute for Integrative Cancer Research at MIT. Pioneer in genetically engineered mouse models to study human cancers. Author of more than 300 scientific papers. Chair of the National Cancer Advisory Board; past president of the AACR. Recipient of the 2026 American Cancer Society Medal of Honor. Elected member of the National Academy of Sciences and National Academy of Medicine.

Prof. Phillip A. Sharp

Nobel Laureate, Special Advisor; Institute Professor, MIT

Winner of the 1993 Nobel Prize in Physiology or Medicine for the discovery of RNA splicing. Institute Professor at MIT; member of the Department of Biology and the Koch Institute for Integrative Cancer Research.

Prof. Jeannie T. Lee

Professor of Genetics, Harvard Medical School; HHMI Investigator

Specializes in epigenetic regulation by long noncoding RNAs, using X-chromosome inactivation as a model system. Co-founded Translate Bio and Fulcrum Therapeutics. Member of the National Academy of Sciences; 2018 Harrington Rare Disease Scholar.

Dr. Ben Ebert, MD, PhD

President and CEO, Dana-Farber Cancer Institute

President and CEO of Dana-Farber Cancer Institute; George P. Canellos Professor of Medicine at Harvard Medical School. Research focuses on the genetics, biology, and therapy of myeloid malignancies. Member of the National Academy of Medicine.

Prof. Adrian Krainer

Professor, Cold Spring Harbor Laboratory

Expert on the role and mechanisms of RNA splicing proteins and how faulty splicing can be corrected. Inventor of the approved SMA drug nusinersen. Scientific founder of Stoke Therapeutics.

Prof. Ben Blencowe

Banbury Chair of Medical Research, University of Toronto

Internationally recognized RNA biologist who has made pioneering contributions to the understanding of the molecular mechanisms controlling alternative splicing and their roles in evolution, development, and disease. Fellow of the Royal Society (UK).

Prof. Maurice Swanson

Professor, University of Florida College of Medicine

Expert on RNA alternative processing regulation during development and neurological/neuromuscular diseases including muscular dystrophy and ALS. Associate Director of the Center for NeuroGenetics at the University of Florida.

Prof. Ed Wild

Professor of Neurology, University College London

Associate Director of UCL's Huntington's Disease Centre; Consultant Neurologist at the National Hospital for Neurology & Neurosurgery, London. Leading expert in clinical care, therapeutic development, trial design, and biomarkers for Huntington's disease.

Amanda L. Garner, PhD

Charles Walgreen Jr. Professor, University of Michigan College of Pharmacy

Director of the Interdepartmental Program in Medicinal Chemistry at University of Michigan. Research integrates chemical biology, medicinal chemistry, and molecular biology for early-stage drug discovery focused on RNA biology therapeutic targets.

Dr. Rob Hershberg, MD-PhD

Venture Partner, Frazier Life Sciences

Co-founded VentiRx Pharmaceuticals. At Celgene (2014–2019), led Immuno-Oncology and was promoted to Chief Scientific Officer, then EVP and Head of Business Development & Global Alliances. Former Assistant Professor at Harvard Medical School. MD-PhD from UCLA/Salk Institute.

Our Partners

Skyhawk's eight Pharma partnerships have contributed upfront payments of over $525 million

Our Investors

Skyhawk has raised over $181 million in equity financing, led by world-class life science investors including Fidelity Management & Research Company, Alexandria Venture Investments, GreatPoint Ventures, ShangPharma Innovation, and Agent Capital. Combined with over $525 million in partnership capital from eight leading pharmaceutical companies, Skyhawk is well-positioned to advance its pipeline.